Russell Biotech Inc. is engaged in the development and commercialization of a unique magnetic separation technology for uses in the research, diagnostic and therapeutic marketplace. Applications include cell separation, protein purification and nucleic acid isolation.
Russell Biotech's initial product is the Quick-Sep CD15 particle used to rapidly eliminate granulocytes prior to immune function analysis by ELISPOT. Granulocytes have been shown to adversely affect ELISPOT assays. It is also important to note that monocytes are not depleted and are in fact enriched. Retention of monocytes is important since they are antigen presenting cells.
